15 September 2014
ByAppeared in BioNews 771
Testing for these variants could identify the one percent of men with a six-fold higher-than-average risk of developing the disease. These men may then benefit from access to regular screening or targeted treatment should they develop cancer.
Professor Malcolm Mason, prostate cancer expert for Cancer Research UK, which helped fund the research, said the study 'continues a quest to unravel the complex picture of the genetic factors that increase a man's risk of prostate cancer'.
The 77 genetic variants identified previously through genome-wide association studies were mainly identified in populations of European decent. This study compared genetic variants from populations with European, African, Japanese and Latino ancestry for the first time. In total, the researchers analysed over 10 million single nucleotide polymorphisms) in over 87,000 men.
The findings, published in the journal Nature Genetics, identified 16 new genetic variants associated with increased prostate cancer risk in European men and seven in men of mixed heritage. One variant was linked to increased risk of early-onset disease. The culmination of these and previous findings mean that scientists can now explain a third of the inherited risk of prostate cancer in European men.
Professor Ros Eeles from the Institute of Cancer Research (ICR) in the UK, a lead author of the study, said: 'We know that there are a few major genes that are rare and significantly affect prostate cancer risk, but what we are now learning is that there are many other common genetic variants that individually have only a small effect on risk, but collectively can be very important. To use the playing cards analogy, sometimes multiple low cards can combine to form a high risk score'.
This study adds to a growing body of evidence supportive of genetic screening for prostate cancer risk. Earlier this year scientists at the ICR developed a screening test to identify men who are most likely to develop an aggressive form of prostate cancer (see BioNews 743) and researchers in Toronto presented a genetic test to help predict the likelihood of prostate cancer returning after treatment (see BioNews 750).
Dr Matthew Hobbs, deputy director of research at Prostate Cancer UK, which also helped fund the study, said: 'There's no doubt that genetic testing for prostate cancer is an exciting area of research. The results of this study could take us a step closer to targeted screening by allowing us to identify those most at risk of the disease based on the genes that they possess'.
A clinical trial, called BARCODE, which aims to genetically screen 5,000 men for prostate cancer, will now investigate if the new genetic markers can improve on other tests for the disease.
The research was a collaboration between the ICR, the University of Cambridge and the University of Southern California in the USA.